Books

Egan, L. (2008) Pharmacology and Therapeutics, Principals to Practice. Saunders, Philadelphia, 2008. Associate Editor. [Details]

Book Chapters

Egan, L. J. & Sandborn, W. J. (1998) 'Drug therapy of Inflammatory Bowel Disease' In: Drugs of Today. [Details]

Egan, L. J. & Phillips, S. F. (2001) 'Ileoanal pouch patient: evaluation of excessive bowel movements' In: n Bayless, T. M. and Hanauer, S. B. B.C. Decker (eds). Advanced therapy of inflammatory bowel disease (2/e) IHamilton. [Details]

Egan, L. J. & Sandborn, W. J. (2003) 'Clinical pharmacology in inflammatory bowel disease: strategies to optimize current medical therapy' In: In Targan, S., Shanahan, F. & Karp, L. C (eds). Inflammatory Bowel Disease, From Bench to Bedside . Kluwer Academic Publishers. [Details]

Egan, L. J. (2004) 'Tumor necrosis factor alpha' In: Encyclopedia of Gastroenterology. In Johnson, L. R. Elsevier (USA). [Details]

Egan, L. J. 'Mechanisms of action of drugs in IBD' In: Falk Symposium. [Details]

Egan, L. J. & Phillips, S. F. 'Ileoanal pouch: frequent evacuation' In: In Bayless, T. M (eds). Advanced Therapy in Gastroenterology and Liver Disease - 5. B.C. Decker, Hamilton. [Details]

 

Peer Reviewed Journals

Egan, L. J., Orren, A., Doherty, J., Wurzner, R. & McCarthy, C. F. (1994) 'Hereditary deficiency of the seventh component of complement and recurrent meningococcal infection: investigations of an Irish family using a novel haemolytic screening assay for complement activity and C7 M/N allotyping'. Epidemiology and Infection, 113 :275-281. [Details]

Walsh, S. V., Egan, L. J., Connolly, C. E., Egan, E. L., Stevens, F. M. & McCarthy, C. F. (1995) 'Enteropathy associated T cell lymphoma; Low frequency of Epstein Barr virus in these tumors'. Modern Pathology, 8 (7). [Details]

Egan, L. J., Walsh, S. V., Stevens, F. M., Connolly, C. E., Egan, E. L. & McCarthy, C. F. (1995) 'Celiac associated lymphoma a single institution experience of 30 cases in the combination chemotherapy era'. Journal of Clinical Gastroenterology, 21 (2):123-129. [Details]

Egan L. J. & Sandborn W. J. (1996) 'Methotrexate for inflammatory bowel disease: pharmacology and preliminary results'. Mayo Clinic Proceedings, 71 (1):69-80. [Details]

Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1998) 'Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision'. Alimentary Pharmacology and Therapeutics, 12 :679-684. [Details]

Egan, L. J., Bylander, J. M., Agerter, D. C. & Edson, R. S. (1998) 'Herpetic whitlow of the toe: an unusual manifestation of infection with Herpes Simplex virus type 2'. Clinical Infectious Diseases, 26 :196-197. [Details]

Egan, L. J, Sandborn, W. J. & Tremaine, W. J. (1998) 'Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine'. American Journal of Gastroenterology, 93 :442-448. [Details]

Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'The intestinal and systemic pharmacokinetics of methotrexate in inflammatory bowel disease patients'. Clinical Pharmacology & Therapeutics, 65 :29-39. [Details]

Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'Inhibition of interleukin-1-stimulated NF- B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity'. Journal of Biological Chemistry, 274 :26448-26453. [Details]

Egan, L. J., Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Mays, D. C., Pike, M. G., Zinsmeister, A. R. & Lipsky, J. J. (1999) 'A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis'. Alimentary Pharmacology & Therapeutics, 13 :1597-1604. [Details]

Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate'. Inflammatory Bowel Diseases, 5 :167-173. [Details]

Egan, L. J. & Baron, T. H. (2000) 'Endoscopic removal of an embedded biliary Wallstent by piecemeal extraction'. Endoscopy, 32 :492-494. [Details]

Egan, L. J. & Murray, J. A. (2000) 'New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors'. Digestive Diseases, 18 :58-63. [Details]

Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (2000) 'Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate in treatment resistant inflammatory bowel diseas'. Inflammatory Bowel Diseases, 6 :286-289. [Details]

Berin, M. C., Darfeuille-Michaud, A., Egan, L. J., Miyamoto, Y. & Kagnoff, M. F. (2002) 'Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF- B and MAP kinase pathways and the upregulated expression of interleukin-8'. Cellular Microbiology, 4 :635-647. [Details]

Egan, L. J., Myhre, G. M., Mays, D. C., Dierkhising, R. A., Kammer, P. P. & Murray, J. A. (2003) 'CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-esophageal reflux disease: variant alleles predict gastric acid suppression, but not esophageal acid exposure or reflux symptoms'. Alimentary Pharmacology & Therapeutics, 172 (12):1521-1528. [Details]

Chen, L-W., Egan, L. J., Li, Z-W., Kagnoff, M. F. & Karin, M. (2003) 'The two faces of IKK and NF- B inhibition, prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion'. Nature Medicine, 9 (5):575-581. [Details]

Egan, L. J., De Lecea, A., Lehrman, E. D., Myhre, G. M., Eckmann, L. & Kagnoff, M. F. (2003) 'Nuclear factor B activation promotes restitution of wounded intestinal epithelial monolayers'. American Journal of Physiology: Cell Physiology, 285 (5):C1028-C1035. [Details]

Egan, L. J., Eckmann, L., Greten, F., Chae, S., Li, Z-W., Myhre, G. M., Robine, S., Karin, M. & Kagnoff, M. F. (2004) 'IKK -dependent NF- B activation provides radioprotection to the intestinal epithelium'. Proceedings of the National Academy of Sciences USA, 101 :2452-2457. [Details]

Maaser, C., Egan, L. J., Birkenbach, M. P., Eckmann, L. & Kagnoff, M. F. (2004) 'Expression of EBI3 and related molecules by human intestinal epithelium'. Immunology, 112 (Issue no 3):437-445. [Details]

Greten, F. R., Eckmann, L., Greten, T. F., Park, J-M., Li, Z-W., Egan, L. J., Kagnoff, M. F. & Karin, M. (2004) 'IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer'. Cell, 118 :285-296. [Details]

Egan, L. J. & Sandborn, W. M. (2004) 'Advances in the treatment of Crohn's disease'. Gastroenterology, 126 (6):1574-1581. [Details]

Colombel, J-F., Loftus, E. V. Jr, Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R. & Sandborn, W. J. (2004) 'The safety profile of Infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients'. Gastroenterology, 126 (1):19-31. [Details]

Myhre, G. M., Toruner, M., Abraham, S. & Egan, L. J. (2004) 'Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution'. American Journal of Physiology: Gastrointestinal and Liver Physiology, 10 . [Details]

Loftus, C. G., Egan, L. J. & Sandborn, W. J. (2004) 'Cyclosporine, Tacrolimus and Mycophenolate Mofetil in the treatment of inflammatory bowel disease'. Gastroenterology Clinics of North America, 33 (2):141-169. [Details]

Egan, L. J. (2004) 'Drug interactions in gastroenterology: mechanisms, consequences and how to avoid'. Clinical Gastroenterology and Hepatology, 2 (9):725-730. [Details]

Thomas, C., Myhre, G. M., Tschumper, R., Sreekumar, R., Jelinek, D., McKean, D. J., Sandborn, W. J., Lipsky, J. J. & Egan, L. J. (2005) 'Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines'. Journal of Pharmacology and Experimental Therapeutics, 312 (2):537-545. [Details]

Toruner M, Harewood GC, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ (2005) 'Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease'. Inflammatory Bowel Diseases, 11 (5):428-434. [Details]

Egan, L. J. and Sandborn, W. J. (2005) 'Positioning novel biologic, probiotic, and apheresis therapies for Chron's disease and ulcerative colitis'. Current Gastroenterology Reports, 7 (6):485-491. [Details]

Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ (2005) 'Acute pancreatitis in Crohn's disease: clinical features and outcomes'. Inflammatory Bowel Diseases, 11 (12):1080-1084. [Details]

Toruner M, Fernandez-Zapico M,Sha JJ, Pham L, Urrutia R, Egan LJ. (2006) 'Anti-anoikis effect of nuclear factor-kappa B through upregulated expresion of osteoprotegerin, BCL-2 and IAP-1'. Journal of Biological Chemistry, 281 (13):8686-8696. [DOI] [Details]

Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. (2006) 'Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice'. Inflammatory Bowel Disease, 12 (1):29-32. [Details]

Solem CA, Loftus EV Jr, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ. (2006) 'The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease'. Clinical Gastroenterology and Hepatology, 4 :822-823. [Details]

Foran E, Garrity-Park M., Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ. (2006) 'Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2'. Journal of Cellular Science, 120 (PT 3):492-501. [Details]

Egan LJ, Derijks LJ, Hommes D. (2006) 'Pharmacogenomics in inflammatory bowel disease'. Clinical Gastroenterology and Hepatology, 4 (1):21-28. [DOI] [Details]

Egan LJ. (2007) 'A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain'. Clinical gastroenterology and Hepatology, 5 (2):170-171. [Details]

Raja Affendi Raja Ali., Egan LJ, (2007) 'Gastroesophageal reflux disease in pregnancy'. Best Practice and Research Clinical Gastroenterology, 21 (5):793-806. [DOI] [Details]

Kang-Decker N, Cao S, Chatteriee S, Yao J, Egan LJ, Semela D, Mukhopadhyay D, Shah V. (2007) 'Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2'. Journal of Cellular Science, 1 (120(Pt 3)):492-501. [Details]

O'Gorman A, Colleran A, Ryan A, Mann J, Egan LJ. (2007) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'. Gastroenterology, 134 (4):929-936. [Details]

Egan LJ. (2007) 'Allopurinol and 6MP: Steering through the therapeutic obstacle course'. Inflammatory Bowel Disease, 13 (10):1312-1313. [DOI] [Details]

Foran E, Egan LJ. (2008) 'Microenvironment to nucleus signaling: Interleukin-6 decreases tumor suppressor gene expression in HCT116 cells through DNMT1-mediated epigenetic silencing'. Presented at Keystone Symposia, Banff, CA, . [Details]

Colleran A, Ryan A, Egan LJ. (2008) 'Longterm suppression of I?Ba by inflammatory cytokines:'. Molecular Mechanisms. Presented at Keystone Symposia, Banff, CA, . [Details]

O'Gorman A, Ryan A, Foran E, Mureau C, Egan LJ. (2008) 'I?Ba as a target for epigenetic silencing in colon cancer'. Presented at Keystone Symposia, Banff CA, . [Details]

Egan LJ. Maaser C. (2008) 'Inflammatory Bowel Diseases'. Pharmacology and Therapeutics, Principles to Practice, 33 :487-503. [Details]

Ryan A, Colleran A, O'Gorman A, Foran E, Egan LJ. (2008) 'Inhibition of NF-?B in colon cancer cells significantly decreases tumour burden and increases host survival time in a mouse model of peritoneal metastasis'. Presented at Keystone Symposia, Banff, CA, . [Details]

Egan LJ. (2008) 'Inflammation and Immunomodulation'. Pharmacology and Therapeutics, Principles to Practice, 11 :157-172. [Details]

Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. (2008) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'. Gastroenterology, 134 (4):929-936. [DOI] [Details]

Solem CA, Loftus EV Jr, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ (2008) 'Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial'. Gastrointest Endosc, 68 (2):255-266. [DOI] [Details]

Plantivaux A, Szegezdi E, Samali A, Egan L. (2009) 'Is there a role for NF?B in TRAIL resistance. Ann N.Y'. Academy Sci, 1171 :38-49. [Details]

Ryan A, Colleran A, O'Gorman A, Foran E, Egan LJ. (2009) 'Inhibition of NF-?B in colon cancer significantly decreases tumour burden and increases survival time in a mouse model of peritoneal metastasis'. Poster Presentation, DDW, Chicago, . [Details]

Plantivaux A, Szegezdi E, Samali A, Egan L. (2010) 'Regulation of NF-?B responses by epigenetic suppression of I?B? expression in HCT116 intestinal epithelial cells'. American Journal of Physiology: Gastrointestinal and Liver Physiology, 299 (1):96-105. [DOI] [Details]

Foran E, Garrity-Park M., Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ. (2010) 'Upregulation of DNA methyltransferase-mediated gene silencing, anchorage independent growth and migration of colon cancer cells by interleukin-6'. Molecular Cancer Research, 8 (4):471-481. [Details]

Rahman MK, Midtling EH, Svingen PA, Xiong Y, Bell MP, Tung J, Smyrk T, Egan LJ, Faubion WA Jr. (2010) 'The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival'. J. Immunol, 184 (12):7247-7256. [Details]

Colleran A, O'Gorman A, Ryan A, Mureau C, Liptrot C, Dockery P, Fearnhead H, Egan L. (2011) 'Autophagosomal IkBa degradation plays a role in the long term control of tumor necrosis factor-a-induced NF-kB activation'. Journal of Biological Chemistry, 286 :22886-22893. [DOI] [Details]

Ali R, Dooley C, Comber H, Newell J, Egan L. (2011) 'Clinical features, treatment and survival of colorectal cancer patients with or without inflammatory bowel disease'. Clinical Gastroenterology and Hepatology, in press, 9 :584-104. [DOI] [Details]

Egan, L. J., Smith, J. R., Truong, F., Kirstein, S., Sugimoto, Y., Narumiya, S., Varki, N. M., Insel, P. A., Kagnoff, M. F. & Eckmann, L. 'Thromboxane A2 and prostacyclin receptors exert opposing effects on the severity of experimental murine colitis'. . [Details]

 

Conference Publications

Plantivaux A, Szegezdi E, Samali A, Egan LJ. (2008) TRAIL resistance in colon cancer cells: is NF-?B involved? APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS [Details]

         

Conference Poster

Egan LJ, Orren A, Doherty J, McCarthy CF. (1994) Hereditary terminal complement deficiency and recurrent meningococcal infection.. National Scientific Medical Meeting. Irish Journal of Medical Science. Conference Poster [Details]

Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. (1994) Lymphoma in celiac disease Improved outcome with intensive combination chemotherapy. World Congresses of Gastroenterology. Conference Poster [Details]